SEC Comment Letter 0000000000-24-009339 to RedHill Biopharma Ltd. (RDHL)
RedHill Biopharma Ltd.
Date: Aug. 15, 2024 · CIK: 0001553846 · Accession: 0000000000-24-009339
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-281417
Letter
August 15, 2024 Dror Ben-Asher Chief Executive Officer RedHill Biopharma Ltd. 21 Ha'arba'a Street Tel Aviv 6473921 Israel Re:RedHill Biopharma Ltd. Registration Statement on Form F-3 Filed August 9, 2024 File No. 333-281417 Dear Dror Ben-Asher: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at 202-551-6761 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Alla Digilova, Esq.
Show Raw Text
August 15, 2024
Dror Ben-Asher
Chief Executive Officer
RedHill Biopharma Ltd.
21 Ha'arba'a Street
Tel Aviv 6473921
Israel
Re:RedHill Biopharma Ltd.
Registration Statement on Form F-3
Filed August 9, 2024
File No. 333-281417
Dear Dror Ben-Asher:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that
the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Chris Edwards at 202-551-6761 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Alla Digilova, Esq.